<DOC>
	<DOCNO>NCT00623610</DOCNO>
	<brief_summary>To examine whether temporary immunosuppression ATG , tacrolimus MMF allow prolong survival beta cell allograft type 1 diabetic patient early chronic complication diabetes .</brief_summary>
	<brief_title>Beta-Cell Transplantation Pre-Uremic Patients With Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<criteria>type 1 insulindependent diabetic patient relatively good general condition nonsmoker body weight &lt; 80 kg Cpeptide &lt; 0.03 nmol/l ( &lt; 0.09 µg/l ) 6 min . glucagon IV ( 1mg ) ( glycemia &gt; 180 mg/dl ) EBV antibody positive cooperative reliable patient give informed consent signature ; patient inform sufficient detail content procedure protocol , indicate potential risk intervention immunosuppressive therapy ; patient also inform withdrawal immunosuppressive therapy patient persistent plasma Cpeptide positivity may result subsequent loss ßcell graft function ; ß cell implant identify clinical trial history thrombosis pulmonary embolism abnormal liver function HLA antibody</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2008</verification_date>
	<keyword>Diabetes mellitus , type 1</keyword>
	<keyword>pancreatic beta cell</keyword>
	<keyword>transplantation</keyword>
</DOC>